Well, Xarelto ACS adcom gave negative vote despite favorable briefing doc, tafamidis got split vote despite very negative briefing doc. If I had to bet one on approval, I would bet on the later one. For ultra orphan indication, surrogate endpoint being reasonable predictor of clinical benefit is an important vote.
Market Data 
Markets 
AI
